Wilmington, Delaware — According to state and local development sources, Incyte plans to build out 517,307 square feet of new space in Wilmington. The company plans to occupy the new space at 1815 Augustine Cut Off in Wilmington, on or about April 1, 2026. According to the company website Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. We are committed to the relentless pursuit of science that can improve the lives of patients. Our unique expertise in medicinal chemistry and biology has enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across Oncology and Inflammation & AutoImmunity. Headquartered in Wilmington, Delaware, Incyte has more than 1,700 employees and operations in North America, Europe and Asia. We are proud to have been recently recognized by Forbes as one of the Worlds Most Innovative Companies. Additionally, Incyte has consecutively been named a Top Employer by Science Magazine, placing #2 on the 2020 list.

To learn more about Incyte, visit http://incyte.com/

Company Contact:
Herve Hoppenot, Chief Executive Officer
https://www.linkedin.com/in/herve-hoppenot-4b912b9/
855-446-2983

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.